
Raquel De Souza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10674882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Molecular Pharmaceutics, 2018, 15, 472-485.	4.6	24
2	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. PLoS ONE, 2018, 13, e0196892.	2.5	5
3	Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. Theranostics, 2018, 8, 2300-2312.	10.0	47
4	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research, 2017, 187, 147-160.	1.5	44
5	Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). Molecular Cancer Therapeutics, 2015, 14, 2060-2071.	4.1	51
6	Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. International Journal of Pharmaceutics, 2015, 488, 154-164.	5.2	16
7	Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents. Journal of Controlled Release, 2015, 219, 313-330.	9.9	10
8	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. Journal of Controlled Release, 2015, 219, 295-312.	9.9	11
9	Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease. Molecular Pharmaceutics, 2015, 12, 3973-3985.	4.6	24
10	A multimodal nano agent for image-guided cancer surgery. Biomaterials, 2015, 67, 160-168.	11.4	45
11	The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Psychopharmacology, 2014, 231, 841-852.	3.1	35
12	Nanotechnology for Multimodality Imaging: Applications in Disease Detection and Treatment Guidance. Frontiers in Nanobiomedical Research, 2014, , 145-193.	0.1	0
13	Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. Molecular Pharmaceutics, 2013, 10, 3315-3322.	4.6	8
14	Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model. , 2013, , .		2
15	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. Journal of Controlled Release, 2012, 158, 379-385.	9.9	29
16	Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer. Molecular Pharmaceutics, 2011, 8, 260-269.	4.6	46
17	Docetaxel Distribution Following Intraperitoneal Administration in Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 90.	2.1	12
18	Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer. Molecular Cancer Therapeutics, 2011, 10, 1289-1299.	4.1	68

RAQUEL DE SOUZA

#	Article	IF	CITATIONS
19	Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 1820-1830.	4.1	36
20	Polymeric drug delivery systems for localized cancer chemotherapy. Drug Delivery, 2010, 17, 365-375.	5.7	158
21	Chitosan–phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. International Journal of Pharmaceutics, 2009, 377, 76-84.	5.2	32
22	Biocompatibility of injectable chitosan–phospholipid implant systems. Biomaterials, 2009, 30, 3818-3824.	11.4	82
23	Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemotherapy and Pharmacology, 2007, 60, 907-914.	2.3	63
21 22	Polymeric drug delivery systems for localized cancer chemotherapy. Drug Delivery, 2010, 17, 365-375. Chitosan–phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. International Journal of Pharmaceutics, 2009, 377, 76-84. Biocompatibility of injectable chitosan–phospholipid implant systems. Biomaterials, 2009, 30, 3818-3824. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemotherapy and	5.2	3: 8: